Last reviewed · How we verify
NCT07082335
Clinical Characteristics and Prognosis of Simultaneous Versus Delayed Resection for Synchronous Colorectal Liver Metastasis: A Nationwide Multicenter Study Utilizing Propensity Score Matching Analysis
trial in Colorectal Cancer (CRC) in 679 participants. Completed in 1 January 2024.
1 January 2021
Quick facts
| Lead sponsor | Shanghai 10th People's Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 679 |
| Start date | 1 January 2019 |
| Primary completion | 1 January 2021 |
| Estimated completion | 1 January 2024 |
| Sites | 1 location across China |
Conditions studied
- Colorectal Cancer (CRC) — all drugs for Colorectal Cancer (CRC) →
Sponsor
Shanghai 10th People's Hospital
Who can join
18 and older, any sex, with Colorectal Cancer (CRC). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Colorectal cancer (CRC) often metastasizes to the liver, with synchronous metastases observed in 20% of cases. Surgical resection is the primary treatment, but the impact of simultaneous and staged resections on clinical outcomes remains unclear. This study employs propensity score matching (PSM) in a nationwide survey to compare clinical characteristics, complications, and survival, providing valuable insights for optimizing the management of colorectal liver metastases.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07082335
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Colorectal Cancer (CRC)
Currently open trials in the same condition.
- NCT07448142 — Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal Cancer · Phase 2 · recruiting
- NCT07223047 — A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agent · Phase 1, PHASE2 · recruiting
- NCT07106892 — Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects Wit · Phase 2 · recruiting
- NCT07152210 — Clinical Study on the Safety and Preliminary Efficacy of CDH17/GUCY2C CAR-T in the Treatment of Patients With Advanced C · NA · recruiting
- NCT07046468 — Smart Pill for Measuring Gut Health in Colon Inflammation and Colon Cancer · recruiting
Other Shanghai 10th People's Hospital trials
Trials by the same sponsor.
- NCT07528040 — An Observational, Multicenter Study to Evaluate the Effectiveness of Guselkumab for the Treatment of Participants With C · not yet recruiting
- NCT07370441 — Amino Acid (15) Peritoneal Dialysis Solution for Nutritional Improvement in Peritoneal Dialysis Patients · Phase 4 · not yet recruiting
- NCT07328100 — Efficacy and Safety of Coenzyme I for Injection on Vascular Aging. · NA · not yet recruiting
- NCT06783296 — Efficacy and Safety of Renal Denervation on Isolated Diastolic Hypertension · NA · not yet recruiting
- NCT07204496 — A Clinical Study on the Safety, Tolerance, and Preliminary Efficacy of γδ-T Cell Injection in the Treatment of Advanced · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07082335 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai 10th People's Hospital
- Last refreshed: 22 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07082335.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing